Palisade Bio Inc (PALI) News

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) --  Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade...

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form POS AM - Post-Effective amendments for registration statement

Form EFFECT - Notice of Effectiveness

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Carlsbad, CA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade...

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

First three Single Ascending Dose cohorts demonstrated no treatment related adverse events Carlsbad, CA...

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses